Related Experiment Video
Updated: Jul 16, 2025
11:05
Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
Published on: September 19, 2014
12.2K
Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy
Xu Cao1, Kristen E Muller2, Mary D Chamberlin2
1Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
Summary
Near-infrared spectral tomography (NIRST) can reliably predict residual cancer burden (RCB) in breast cancer patients early during neoadjuvant chemotherapy (NAC). Early changes in total hemoglobin (HbT) measured by NIRST effectively forecast treatment response and patient outcomes.
Area of Science:
- Oncology
- Medical Imaging
- Biomedical Engineering
Background:
- Neoadjuvant chemotherapy (NAC) is a standard treatment for breast cancer.
- Accurate prediction of treatment response, such as residual cancer burden (RCB), is crucial for optimizing patient management.
- Current methods for assessing RCB often rely on post-treatment histopathology, delaying critical treatment decisions.
Purpose of the Study:
- To evaluate near-infrared spectral tomography (NIRST) as a prognostic tool for predicting residual cancer burden (RCB) in breast cancer patients undergoing NAC.
- To determine if early treatment response measurements using NIRST can reliably forecast RCB.
- To assess the potential of NIRST for improving breast cancer patient management strategies.
Main Methods:
- Thirty-five breast cancer patients receiving NAC were enrolled.
- Near-infrared spectral tomography (NIRST) imaging was performed at multiple time points: pre-treatment, end of cycle 1, mid-treatment, and post-NAC.
- Total hemoglobin (HbT) levels in the tumor and contralateral breast were quantified. The normalized percentage change in HbT (ΔHbT%) was calculated.
- RCB was assessed post-NAC by a pathologist. Logistic regression analyzed the predictive value of ΔHbT% for RCB classification.
Main Results:
- The normalized percentage change in total hemoglobin (ΔHbT%) at the end of the first NAC cycle demonstrated excellent prognostic capability.
- ΔHbT% effectively differentiated between RCB-0 and RCB-I/II/III (P < 0.001, AUC=0.97, accuracy=0.90).
- ΔHbT% also distinguished RCB-II from RCB-0/I/III (P < 0.001, AUC=0.94, accuracy=0.83), indicating high predictive accuracy.
Conclusions:
- Near-infrared spectral tomography (NIRST) shows significant promise as a non-invasive prognostic tool for breast cancer.
- Early assessment of treatment response via NIRST-derived ΔHbT% can reliably predict residual cancer burden (RCB).
- NIRST integration into clinical workflows offers potential for improved breast cancer patient management and personalized treatment strategies.
